Abstract 87P
Background
Survival outcome in rectal cancer primarily determined by nodal status and stage of tumour. Though nodal invasion is strong prognostic indicator in rectal cancer, there exists marked heterogenecity within stage III patients. We investigated the prognostic impact of ratio of positive lymph nodes to total number of retrieved nodes (LNR), ratio of positive to negative lymph nodes (PN-LNR) and negative to positive nodes (NP-LNR) on survival in patients with node positive rectal cancers.
Methods
This is a retrospective analysis of 336 patients of rectal cancer who underwent surgery and adjuvant therapy between 2011 to 2014. The node positive patients were grouped into two groups based on quartiles of LNR <0.2 and >0.2, PN-LNR <0.36 and >0.36 and NP-LNR <2.38 and >2.38. The association between LNR, PN-LNR and NP-LNR and survival was evaluated by the Kaplan-Meier method and multivariate analysis with covariates of prognostic significance in univariate analysis.
Results
Patients classified as LNR <0.2 and >0.2 had a 5-year OS of 86.8 and 64.4 (p < 0.001) and DFS of 85.4 and 59.9 respectively (p < 0.001). The 5-year OS rate for PN-LNR <0.36 and >0.36 were 85.1 and 55.1 (p < 0.001) and DFS of 83.9 and 49.3 respectively (p < 0.001). The 5-year OS rate for NP-LNR <2.38 and >2.38 were 53.1 and 87.3 (p < 0.001) and DFS of 47.5 and 85.6 respectively (p < 0.001). OS and DFS of stage III A, III B, III C were 80.3,75.3, and 53.3 (p < 0.001) and 79.5,71.8 and 47.8 respectively (p < 0.001). On univariate analysis, pN status, sex, grade, histology of tumour, LNR, PN-LNR, NP-LNR were found to be significator factors for OS. On multivariate analysis, NP-LNR was found to be significant factor for OS. (p < 0.001, HR = 17.857; [3.557-89.657]). Factors that were found to be significant for DFS were pN status, LNR, PN-LNR, NP-LNR on univariate analysis and NP-LNR on multivariate analysis. (p < 0.001, HR = 11.41; [1.928-67.634]). NP-LNR is found to a significant factor for OS and DFS both on univariate and multivariate analysis.
Conclusions
The NP-LNR was recognised as an independent prognostic factor in node positive rectal cancer patients. Hence, it can be used as an independent prognostic factor and permits superior prognostic stratification in stage III rectal cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Kidwai Memorial Institute of Oncology.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
221P - Comparative analysis of first-line immune checkpoint inhibitor versus carboplatin-based chemotherapy for cisplatin-ineligible metastatic urothelial carcinoma: A multicenter, retrospective real-world evidence
Presenter: Hsiang‐Lan Lai
Session: Poster display session
Resources:
Abstract
222P - Does tumor grade really improve the prognostic ability of the staging system for men with penile cancer: A SEER database analysis
Presenter: Ravi Kanodia
Session: Poster display session
Resources:
Abstract
223TiP - EV-301: A phase III trial in progress evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma
Presenter: Daniel Petrylak
Session: Poster display session
Resources:
Abstract
230P - Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort
Presenter: Lingying Wu
Session: Poster display session
Resources:
Abstract
231P - Cost-effectiveness of olaparib vs routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore
Presenter: David SP Tan
Session: Poster display session
Resources:
Abstract
233P - Incorporation of correlative studies in ovarian cancers in the era of precision medicine: Assessment of accountability and utility
Presenter: Nadia Hitchen
Session: Poster display session
Resources:
Abstract
234P - Implementation of mainstream BRCA testing in epithelial ovarian cancer in a tertiary centre
Presenter: Edbert Wong
Session: Poster display session
Resources:
Abstract
235P - The efficacy of radiation therapy in ovarian carcinoma: A propensity score analysis of a population-based study
Presenter: Jian-Guo Zhou
Session: Poster display session
Resources:
Abstract
236P - Front-line maintenance therapy for platinum-sensitive ovarian cancer: What’s next PARP inhibitors?
Presenter: Han Gong
Session: Poster display session
Resources:
Abstract
237P - PARP inhibitor in platinum resistant ovarian cancer: Single center real world experience
Presenter: Saphalta Baghmar
Session: Poster display session
Resources:
Abstract